title: Compassionate approval process for experimental gene-based products.
authors.forename: Gladice
authors.initials: G
authors.lastname: Wallraven
authors.forename: John J
authors.initials: JJ
authors.lastname: Nemunaitis
authors.forename: Phillip B
authors.initials: PB
authors.lastname: Maples
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D017277:Drug Approval / Q000379:methods*; D004645:Empathy; D005260:Female; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016864:Li-Fraumeni Syndrome / Q000188:drug therapy; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013727:Terminal Care / Q000379:methods*; D035703:Therapies, Investigational / Q000379:methods* / Q000523:psychology; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration; D014765:Viral Vaccines / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D019496:Cancer Vaccines; D014765:Viral Vaccines; C512972:advexin; D003841:Deoxycytidine; D000093542:Gemcitabine